期刊文献+

螺内酯治疗难治性高血压23例疗效观察 被引量:7

Efficacy of spironolactone in the treatment of resistant hypertension
下载PDF
导出
摘要 目的观察螺内酯治疗难治性高血压的疗效。方法把45例门诊难治性高血压患者随机分成治疗组23例和对照组22例,对照组接受改善生活方式和包括利尿剂在内的抗高血压药物的基础治疗,治疗组在基础治疗的同时加用螺内酯(醛固酮拮抗剂)20mg,每天一次,测量治疗前、治疗3周后所有患者血压及检测治疗组治疗前后血钾水平。结果治疗组收缩压、舒张压治疗3周后与治疗前比较,差异有统计学意义,P<0.05,治疗组治疗前后血钾均在正常范围内。结论在定期检测血钾的情况下,难治性高血压患者在利尿剂、钙离子拮抗剂和血管紧张素转换酶抑制剂基础上加用小剂量螺内酯可取得满意的降压效果。 Objective To observe the effect of spironolactone on resistant hypertension.Methods 45 out-patients with resistant hypertension were randomly divided into two groups:treatment group(n=23) and control group(n=22).The cases in control group received antihypertensive drugs including diuretics and improved the lifestyle,while the others continued the basic treatment plus spironolactone(aldosterone antagonist)20mg once a day.All patients,blood pressure and the plasma potassium of patients in treatment group were respectively measured pre-treatment and after 3 weeks treatment.Results After 3 weeks treatment,the systole blood pressure and diastole blood pressure were significantly different from pre-treatment in treatment group(P0.05),meanwhile the levels of serum potassium were in the normal range in treatment group before and after treatment.Conclusion In regular inspection of plasma potassium,the patients with resistant hypertension can take satisfactory antihypertensive effect by adding low dose spironolactone based on diuretics calcium channel blockers(CCB) and angiotensin-converting enzyme inhibitors(ACEI).
机构地区 沛县人民医院
出处 《海南医学》 CAS 2011年第1期25-27,共3页 Hainan Medical Journal
关键词 螺内酯 难治性高血压 Spironolactone Resistant hypertension
  • 相关文献

参考文献8

二级参考文献70

  • 1陈广华,石增成,张梅.醛固酮拮抗剂依普利酮治疗高血压病研究进展[J].中国心血管病研究,2004,2(12):987-990. 被引量:9
  • 2周长宏,宋文宣.醛固酮对心血管的有害作用与醛固酮拮抗剂的临床应用[J].中国医刊,2005,40(2):17-20. 被引量:3
  • 3董琦,魏梅,刘坤申.醛固酮受体拮抗剂在慢性心力衰竭中的应用[J].中华内科杂志,2005,44(7):545-547. 被引量:13
  • 4方展,朱忠华,张春,熊京.螺内酯对梗阻性肾病大鼠肾间质纤维化的防治作用[J].中华肾脏病杂志,2006,22(1):50-52. 被引量:12
  • 5Daniel A. Aldosterone and the vasculature:mechanisms mediating resistant hypertension. J Clin Hypertens, 2007,9 (Suppl 1 ) : 13-18.
  • 6Mancia G, De Backer G, Dominiczak A ,et al. 2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Sociely of Hypertension (ESH) and of the European Society of Cardiology (ESC).Eur Heart J,2007,28:1462-1536.
  • 7The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs. diuretic:the Antihy pertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT). JAMA, 2002,288 : 2981-2997.
  • 8Aucott L, Poobalan A, Smith WC, et al. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension,2005,45 : 1035-1041.
  • 9Lewis E J, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesarlan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001,345 851-860.
  • 10Lavie P, Hoffstein V. Sleep apnea syndrome:a possible contributing factor to resistant hypertension. Sleep, 2001,24 : 721-725.

共引文献51

同被引文献36

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部